#bacterial infections

[willowreader]

My husband who worked in healthcare gasped when he looked at the graphs. Our immune systems have been damaged by Covid. Click on the link View on Twitter to see the post

A few people have asked me where the graphs come from. This is the work of someone who has looked at the data and posted their observations. If you can't access Twitter to see the rest of the post then I cant help you. There are explanations there about the graphs.. I am sorry I can't give you more information. I tried to copy more of this thread but Tumblr won't recognize the link. As far as I know the information is valid, but as we all know you must question everything today.

I went back and copied 2 of the sources used for the graphs in the thread. There were some questions for others on the data used, and this was what the person who posted said he used. I do not have the background to ascertain how accurate the graphs are. This is the best I can do.

Other graphs were also posted which were discussed.

[wikipediapictures]

Piperacillin/tazobactam

[vizthedatum]

My doctors finally confirmed an infection that I thought I had today (well the test results came in yesterday, and I messaged three of my doctors and they all interpreted it).

Anyway (I know my life is a lot! Chronic health issues are A LOT), I just posted this on facebook:

—

I am about to start a 10 day course of antibiotics for a serious bacterial infection (not a UTI or STI - pls DM to ask) so I will be more immunocompromised than usual.

I am not contagious (it’s not airborne) but the antibiotic course will weaken me even though it’s treating me.

I have suspected I’ve had this underlying infection for about two months now, and honestly… because of my chronic pain and living with pain/disability for so long, I have just… dealt with it.

What choice do I have? I am simply now trying to be more and more assertive to my doctors. I have been trying to tell them.

I am tired.

I’m actually having a higher energy day today than normal and have been catching up on chores. I even got flu and covid vaccinated today!

But this post is to say:

I’m not gonna cancel the social plans I have this week but I will be masking so I don’t get sick with something else (like the strain of covid that’s not accounted for by the latest vaccine), and I would appreciate if you would mask around me too (and have clean, washed hands) since my immune system is not doing that great right now.

—

While writing this message, my pharmacy just called: my antibiotic is not covered by my insurance and costs over 4000 dollars (to which I said WTF I LITERALLY TESTED POSITIVE), so I will be in yet another prior auth hell (my bladder meds are still in holdup).

(And also they told me that my T vial is only good for 28 days and they have to give me a new one for next week’s injection)

[bpod-bpod]

Potential Pathogen

These yellow spheres are Staphylococcus aureus bacteria on the surface of a human immune cell (blue). They are found in, and on, about a third of the human population and are generally harmless except, that is, for when they’re not. S. aureus can cause severe and potentially fatal infections of the skin, soft tissues, bone and blood, and especially dangerous are the drug-resistant strains – so called, methicillin-resistant S. aureus (MRSA). The bacteria were thought to mainly inhabit the skin and nose, but recent research shows they are most abundant in the gut. This discovery led researchers to test whether probiotics – oral doses of friendly bacteria – could suppress S. aureus colonisation. And they could – by around ninety-five percent. Probiotics work more slowly than traditional antibiotics for tackling infections, but they can be taken for much longer without harm, and will likely be able to tackle MRSA strains when regular drugs cannot.

Written by Ruth Williams

Image from the NIH, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda MD, USA

Research by Pipat Piewngam & Sunisa Khongthong, et al, NIAID and Rajamangala University of Technology Srivijaya, Thailand

Image in the Public Domain

Research published in Lancet Microbe, January 2023

You can also follow BPoD on Instagram, Twitter and Facebook

[somethingthatsaysbubbles]

I’m collecting bacterial infections like a damn Pokémon trainer. 🤣 My C.Diff has been taken care of, but I have H. Pylori.

Good News: It’s treatable.

Bad News: Due to allergies, I’m starting Quadruple Therapy which involves Flagyl (which is bad-time-side-effects-city).

Does anyone wanna give me their stomach? 🖤

[rodspurethoughts]

FDA Approves Omisirge, a Cell Therapy for Blood Cancer Patients Undergoing Stem Cell Transplantation

The FDA has recently approved a cell therapy called Omisirge (omidubicel-onlv) for patients with blood cancers who are undergoing stem cell transplantation. This allogeneic cord blood-based cell therapy can help speed up the recovery of neutrophils in the body, a type of white blood cell, and reduce the risk of infection. Omisirge is intended for use in adults and pediatric patients 12 years and…

[ricisidro]

I got a pimple inside my ear according to the ENT doctor who examined me with the use of an otoscope.

Treatment for a pimple in the ear includes home remedy Aplosyn otic solution 5ml ear drops to be applied 3 drops, 3 times daily, for 2 weeks.

#pimple #ear #earinfection #otitis #otitisexterna #bacterialinfection

[willowreader]

https://www.h-h-c.com/the-complexity-of-co-infections-in-the-era-of-covid-19/

If you click on this article it explains all the secondary infections you can get with COVID. I have done a lot of reading about Covid, but this is the first article I have seen that covers this topic.

[creativeera]

Enrofloxacin Market is witnessing growth by increasing livestock diseases

The enrofloxacin market comprises antibacterial agents that are widely used for treating bacterial infections in animals. Enrofloxacin comes in various forms like tablets, injectables, and premixes that provide effective treatment for respiratory diseases, metritis, and mastitis in livestock. It demonstrates broad-spectrum antibacterial activity against both gram-positive and gram-negative bacteria. Enrofloxacin minimizes mortality and improves weight gain in infected animals. The global demand for animal-derived food products is increasing rapidly, placing high pressure on livestock farmers to ensure disease prevention among animals. The Global Enrofloxacin Market is estimated to be valued at US$ 541.91 Billion in 2024 and is expected to exhibit a CAGR of 15% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the enrofloxacin market are Sunny Optical Technology Group Co. Ltd., Foxconn Technology Co. Ltd., STMicroelectronics N.V., OmniVision Technologies Inc., Chicony Electronics Co. Ltd., Sharp Corporation, LG Innotek Company Ltd, Partron Co. Ltd., Lite-On Technology Corp., LuxVisions Innovation, and Samsung Electro-Mechanics Co. Ltd. These players are focusing on expanding their production facilities and product portfolios to cater to the growing demand. The Enrofloxacin Market Demand is increasing in the livestock sector due to the rising prevalence of bacterial diseases among animals. With the growth of animal farming industries in Asia Pacific and Latin America, the consumption of enrofloxacin is expected to surge substantially in the coming years. The leading manufacturers are strategizing their global expansion plans by entering into partnerships with local distributors across countries. They are also adopting acquisitions and mergers as key strategies to broaden their international footprints and service wider customer bases. Market Key Trends The increasing global meat consumption is one of the key trends driving the enrofloxacin market. As the demand for meat and poultry rises tremendously year-on-year, farmers are compelled to produce more livestock in a limited period, making animals more vulnerable to diseases. Enrofloxacin Market Companies is augmenting the demand for effective antibacterial drugs like enrofloxacin for safeguarding animal health. Moreover, the growing awareness among farmers about enrofloxacin's benefits over conventional antibiotics is propelling the product demand.

Porter's Analysis Threat of new entrants: Low barriers and costs for new companies to enter the market due to availability of generic formulations and APIs. Bargaining power of buyers: Large customer base such as veterinarians and livestock farms have moderate bargaining power due to availability of substitutes. Bargaining power of suppliers: Few big players control supply of key APIs resulting in high bargaining power of suppliers. Threat of new substitutes: Threat of substitutes is low as there are limited alternatives for the treatment of bacterial infections in animals. Competitive rivalry: Intense competition among existing players to gain market share through generic formulations and cost leadership strategies. Geographical Regions North America holds the largest share of the global enrofloxacin market owing to high demand for veterinary drugs and livestock farming. The United States accounts for the major market in the region. Asia Pacific is expected to witness the fastest growth during the forecast period driven by rising meat consumption, increase in livestock population, and growing awareness about animal health in India and China.

Get more insights on Enrofloxacin Market

Unlock More Insights—Explore the Report in the Language You Prefer

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

[aingopharma]

Aingo Pharma Faropenem Sodium Tablets

[jcmarchi]

MIT spinout Arnasi begins applying LiquiGlide no-stick technology to help patients

New Post has been published on https://thedigitalinsider.com/mit-spinout-arnasi-begins-applying-liquiglide-no-stick-technology-to-help-patients/

MIT spinout Arnasi begins applying LiquiGlide no-stick technology to help patients

The no-stick technology invented by Professor Kripa Varanasi and David Smith SM ’11, initially commercialized as LiquiGlide in 2012, went viral for its uncanny ability to make materials that stick to their containers — think ketchup, cosmetics, and toothpaste — slide out with ease.

Now, the company that brought you Colgate no-stick toothpaste is moving into the medical space, and the applications could improve millions of lives. The company, which recently rebranded as the Arnasi Group, has developed an ambitious plan to launch three new biomedical products over the next four years.

The first of those products, called Revel, is a deodorizing lubricant designed for ostomy pouches, which are used by individuals to collect bodily waste after digestive system surgeries. Up to 1 million people rely on such pouches in the United States. Ostomy pouches must be emptied multiple times per day, and issues resulting from sticking or clogging can cause embarrassing, time-consuming situations for the people relying on them.

Arnasi’s deodorizing lubricant can prevent clogging and simplify the ostomy pouch cleaning process. Unlike other options available, one application of its lubricant works for the entire day, the Arnasi team says, and they designed a single unit dose that fits in your pocket for added convenience.

An ostomy pouch “significantly impacts a person’s lifestyle,” Varanasi says. “They need to keep it clean, and they need to use it at all times. We are solving a very important problem while helping people by giving their dignity and lifestyles back.”

Revel, Arnasi’s FDA-registered product, officially launched this month, and it has already received promising feedback from nurses and patients.

Margaret is a nurse who relies on an ostomy pouch herself and cares for patients who need them after receiving colostomies and ileostomies. She received samples of Revel at a recent conference and says it could dramatically improve both her and her patients’ lives.

“These pouches need to be emptied frequently, and sometimes that’s very difficult to do,” she says. “This particular product makes everything slide out without any problems at all, and it’s a wonderful improvement. It also lasts long enough to empty the pouch three to four times, which is great because you don’t have to carry a bunch of this stuff around.”

Margaret’s experience echoes feedback Arnasi’s team has heard from many others.

“When we showed it to the nurses, they were blown away with the product,” says Arnasi CEO Dan Salain. “They asked us to get this product out to the market as fast as we could, and so that’s what we’re doing.”

Arnasi’s next medical products will be used to prevent biofilm and bacterial infections caused by implants and catheters, and will also help people with cystic fibrosis.

“We want to create products that really help people,” Salain says. “Anything that’s implantable in the body, whether it’s a catheter, a hip, knee, or joint replacement, a breast implant, a bladder sling — those things lend themselves to our technology.”

From packages to patients

Varanasi initially developed Arnasi’s liquid-impregnated surface technology with Smith, Arnasi’s co-founder and current CTO, when Smith was a graduate student in Varanasi’s lab. The research was initially funded by the MIT Energy Initiative and the MIT Deshpande Center to work on solid-liquid interfaces with broad applications for energy, water, and more.

“There’s this fundamental friction constraint called the no-slip boundary condition between a liquid and a solid, so by creating a new surface in which we can infuse a liquid that is less viscous, we can now get the product to easily slide on surfaces,” Varanasi explains. “That aha moment meant we could get around a fundamental constraint in fluid dynamics.”

Still, sticky surfaces are everywhere, and the scientific co-founders had to decide where to apply their technology first. Shortly after the invention, Varanasi was at home trying to decide on the best application when he saw his wife across the kitchen table trying to get honey out of a bottle. It was another aha moment.

Soon after, Varanasi’s team entered the MIT $100K Entrepreneurship Competition. The competition — and the corresponding videos of ketchup and other materials sliding out their bottles with ease — created a media storm and a frenzy of attention.

“The press exploded,” Varanasi says. “For three months, my phone didn’t stop ringing. My group website crashed. There was a lot of market pull and in response, we founded the company.”

Arnasi, still operating as LiquiGlide, licensed the intellectual property from MIT’s Technology Licensing Office and eventually signed large deals with some of the world’s biggest consumer packaged goods companies, who used it to create products like fully recyclable toothpaste.

“There is so much waste just because we can’t get all of the product, be it food, cosmetics, or medical products, out of containers,” Varanasi says. “Fifty billion-plus packages are sold every year, and 5 to 10 percent of product is left behind on average. So, you can imagine the CO2 footprint of the wasted product. And even though a lot of this is in recyclable packaging, they can’t be recycled because you need to wash out all the product. The water footprint of this is huge, not to mention the wasted product.”

While all of that was going on, Arnasi’s team was also looking into the biomedical space. For instance, Varanasi’s lab previously showed the technology could be used to prevent occlusion from blood clots and thrombosis and reduce biofilm formation, among other applications.

After studying the industry and speaking with patients and nurses, Arnasi realized a better lubricant for ostomy pouches could improve millions of people’s lives.

“Stool accumulates in these pouches outside of people’s bodies, and they need to empty it up to eight times a day,” explains Brienne Engel, Arnasi’s director of business development. “That process has a lot of challenges associated with it: It can be difficult to drain, leaving a lot of mass behind, it takes a long time to drain, so you can spend a long time in a restroom trying to clear out your pouch, and then there’s something called pancaking that can push the pouch off the [surgical opening], introducing issues like leakage, odor, and failure of the ostomy pouching system.”

Ostomy and beyond

Arnasi’s ostomy lubricant, Revel, is the first non-water-based solution on the market, and as-yet unpublished third-party testing has shown it allows for faster, more complete pouch drainage, along with other benefits.

“A lot of the existing brands treat their consumers like patients, but what we’ve found is they want to be treated like people and have a consumer experience,” Salain says. “The magic we saw with our toothpaste product was people got this amazing consumer experience out of it, and we wanted to create the same thing with Revel.”

Now Arnasi is planning to use its technology in medical products for skin infections, cystic fibrosis, and in implantable catheters and joint replacements. Arnasi’s team believes those last two use cases could prevent millions of deadly infections.

“When people are getting hemodialysis catheters, they have a 33 percent risk of developing infections, and those that do get those infections have a 25 percent chance of dying from them,” Engel says. “Taking our underlying technology and applying it to catheters, for example, imparts anti-biofilm properties and also prevent things like thrombosis, or blood clotting on the outside of these catheters, which is a problem in and of itself but also provides a space for bacteria to seed.”

Ultimately, Varanasi’s team is balancing making progress on its biomedical applications while exploring other avenues for its technology — including energy, manufacturing, and agriculture — to maximize its impact on the world.

“We think of this as a company with many companies within it because of all the different areas that it can impact. Liquid-solid interfaces are ubiquitous, viscous products are everywhere, and deploying this technology to solve difficult problems has been a dream,” Varanasi says. “It’s a great example of how MIT technology can be used for the benefit of humankind.”

[anftherapy]

Learn everything you need to know about stomach inflammation — causes, symptoms, and treatment solutions. 

[townpostin]

Monsoon Season Brings Spike in Infections in Jamshedpur

Jamshedpur sees a rise in bacterial and fungal infections with the arrival of monsoon, reports MGM Hospital. MGM Hospital has reported an increase in cases of bacterial and fungal infections such as ringworm, itching, boils, and pimples as the monsoon season sets in Jamshedpur. JAMSHEDPUR – As the monsoon season arrives, Jamshedpur is experiencing a noticeable increase in bacterial and fungal…